As insufficient NRF2 signaling during chronic oxidative stress is associated with several diseases including neurodegenerative, vascular, and metabolic disorders as well as cancer, the DMF-mediated modulation of the KEAP1-NRF2 complex is becoming increasingly explored as a potential therapeutic strategy. The gene discussed is NFE2L2; the disease is cancer.